Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 3/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | USP2 | O75604 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2322353 | 0.95 | POLB (0.50) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2318096 | 0.94 | POLB (0.49) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2323535 | 0.94 | POLB (0.56) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL12301129 | 0.91 | POLB (0.51) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2320298 | 0.90 | POLB (0.53) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2321852 | 0.89 | POLB (0.53) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2450528 | 0.88 | POLB (0.53) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2443108 | 0.87 | ALDH1A1 (0.53) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2318987 | 0.87 | ALDH1A1 (0.50) | POLBALDH1A1LMNAMAPK1MAPT | |
| SCHEMBL2323261 | 0.85 | ALDH1A1 (0.50) | POLBALDH1A1LMNAMAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | disclosed |
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-09-22 | — | — | US | disclosed |
| EP-2352733-A1 | BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN | Merck Patent GmbH (DE) | 2011-08-10 | — | — | EP | disclosed |
| WO-2010060532-A1 | BENZONAPHTYRIDINE COMPOUNDS USED AS INHIBITORS OF AUTOTAXIN | MERCK PATENT GMBH (DE) | 2010-06-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230471-A1 | BENZONAPHTYRIDINE COMPOUNDS AS INHIBITORS OF AUTOTAXIN | ENPP2, TPX2, TPD52L2 | POLB 3834/4885ALDH1A1 4584/4885LMNA 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.